A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor γ-activating properties

Mauricio J. Reginato, Shannon T. Bailey, Samuel L. Krakow, Chieko Minami, Shinichi Ishii, Hideho Tanaka, Mitchell A. Lazar

Research output: Contribution to journalArticle

174 Citations (Scopus)

Abstract

Thiazolidinediones (TZDs) constitute an exciting new class of antidiabetic compounds, which function as activating ligands for peroxisome proliferator-activated receptor γ (PPARγ). Until now, there has been an excellent correlation between in vivo hypoglycemic potency and in vitro binding and activation of PPARγ by TZDs. We have characterized MCC-555, a novel thiazolidinedione ligand for PPARγ with unique functional properties. The antidiabetic potency of this compound is greater than that of other TZDs, including BRL49653, yet its binding affinity for PPARγ is less than 1/10 that of BRL49653. The effect of MCC-555 binding on PPARγ transcriptional activity is highly context-specific such that it can function as a full agonist, partial agonist, or antagonist depending on the cell type or DNA binding site. These transcriptional properties are partly explained by unique partial agonism of coactivator recruitment to PPARγ. The properties of MCC- 555 are mechanistically distinct from those of the estrogen receptor partial agonist and antagonist tamoxifen because the N terminus of PPARγ is not required for activation by MCC-555, and MCC-555 does not stimulate corepressor recruitment to PPARγ. The context selectivity of MCC-555 may contribute to its enhanced hypoglycemic potency in vivo despite reduced affinity for PPARγ relative to other TZDs.

Original languageEnglish
Pages (from-to)32679-32684
Number of pages6
JournalJournal of Biological Chemistry
Volume273
Issue number49
DOIs
Publication statusPublished - 1998 Dec 4
Externally publishedYes

Fingerprint

Peroxisome Proliferator-Activated Receptors
Hypoglycemic Agents
Thiazolidinediones
rosiglitazone
Chemical activation
Ligands
2,4-thiazolidinedione
Co-Repressor Proteins
Tamoxifen
Estrogen Receptors
netoglitazone
Binding Sites
DNA

ASJC Scopus subject areas

  • Biochemistry

Cite this

A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor γ-activating properties. / Reginato, Mauricio J.; Bailey, Shannon T.; Krakow, Samuel L.; Minami, Chieko; Ishii, Shinichi; Tanaka, Hideho; Lazar, Mitchell A.

In: Journal of Biological Chemistry, Vol. 273, No. 49, 04.12.1998, p. 32679-32684.

Research output: Contribution to journalArticle

Reginato, Mauricio J. ; Bailey, Shannon T. ; Krakow, Samuel L. ; Minami, Chieko ; Ishii, Shinichi ; Tanaka, Hideho ; Lazar, Mitchell A. / A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor γ-activating properties. In: Journal of Biological Chemistry. 1998 ; Vol. 273, No. 49. pp. 32679-32684.
@article{37300bbf4bf141ca848e05d6a948f9ce,
title = "A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor γ-activating properties",
abstract = "Thiazolidinediones (TZDs) constitute an exciting new class of antidiabetic compounds, which function as activating ligands for peroxisome proliferator-activated receptor γ (PPARγ). Until now, there has been an excellent correlation between in vivo hypoglycemic potency and in vitro binding and activation of PPARγ by TZDs. We have characterized MCC-555, a novel thiazolidinedione ligand for PPARγ with unique functional properties. The antidiabetic potency of this compound is greater than that of other TZDs, including BRL49653, yet its binding affinity for PPARγ is less than 1/10 that of BRL49653. The effect of MCC-555 binding on PPARγ transcriptional activity is highly context-specific such that it can function as a full agonist, partial agonist, or antagonist depending on the cell type or DNA binding site. These transcriptional properties are partly explained by unique partial agonism of coactivator recruitment to PPARγ. The properties of MCC- 555 are mechanistically distinct from those of the estrogen receptor partial agonist and antagonist tamoxifen because the N terminus of PPARγ is not required for activation by MCC-555, and MCC-555 does not stimulate corepressor recruitment to PPARγ. The context selectivity of MCC-555 may contribute to its enhanced hypoglycemic potency in vivo despite reduced affinity for PPARγ relative to other TZDs.",
author = "Reginato, {Mauricio J.} and Bailey, {Shannon T.} and Krakow, {Samuel L.} and Chieko Minami and Shinichi Ishii and Hideho Tanaka and Lazar, {Mitchell A.}",
year = "1998",
month = "12",
day = "4",
doi = "10.1074/jbc.273.49.32679",
language = "English",
volume = "273",
pages = "32679--32684",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "49",

}

TY - JOUR

T1 - A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor γ-activating properties

AU - Reginato, Mauricio J.

AU - Bailey, Shannon T.

AU - Krakow, Samuel L.

AU - Minami, Chieko

AU - Ishii, Shinichi

AU - Tanaka, Hideho

AU - Lazar, Mitchell A.

PY - 1998/12/4

Y1 - 1998/12/4

N2 - Thiazolidinediones (TZDs) constitute an exciting new class of antidiabetic compounds, which function as activating ligands for peroxisome proliferator-activated receptor γ (PPARγ). Until now, there has been an excellent correlation between in vivo hypoglycemic potency and in vitro binding and activation of PPARγ by TZDs. We have characterized MCC-555, a novel thiazolidinedione ligand for PPARγ with unique functional properties. The antidiabetic potency of this compound is greater than that of other TZDs, including BRL49653, yet its binding affinity for PPARγ is less than 1/10 that of BRL49653. The effect of MCC-555 binding on PPARγ transcriptional activity is highly context-specific such that it can function as a full agonist, partial agonist, or antagonist depending on the cell type or DNA binding site. These transcriptional properties are partly explained by unique partial agonism of coactivator recruitment to PPARγ. The properties of MCC- 555 are mechanistically distinct from those of the estrogen receptor partial agonist and antagonist tamoxifen because the N terminus of PPARγ is not required for activation by MCC-555, and MCC-555 does not stimulate corepressor recruitment to PPARγ. The context selectivity of MCC-555 may contribute to its enhanced hypoglycemic potency in vivo despite reduced affinity for PPARγ relative to other TZDs.

AB - Thiazolidinediones (TZDs) constitute an exciting new class of antidiabetic compounds, which function as activating ligands for peroxisome proliferator-activated receptor γ (PPARγ). Until now, there has been an excellent correlation between in vivo hypoglycemic potency and in vitro binding and activation of PPARγ by TZDs. We have characterized MCC-555, a novel thiazolidinedione ligand for PPARγ with unique functional properties. The antidiabetic potency of this compound is greater than that of other TZDs, including BRL49653, yet its binding affinity for PPARγ is less than 1/10 that of BRL49653. The effect of MCC-555 binding on PPARγ transcriptional activity is highly context-specific such that it can function as a full agonist, partial agonist, or antagonist depending on the cell type or DNA binding site. These transcriptional properties are partly explained by unique partial agonism of coactivator recruitment to PPARγ. The properties of MCC- 555 are mechanistically distinct from those of the estrogen receptor partial agonist and antagonist tamoxifen because the N terminus of PPARγ is not required for activation by MCC-555, and MCC-555 does not stimulate corepressor recruitment to PPARγ. The context selectivity of MCC-555 may contribute to its enhanced hypoglycemic potency in vivo despite reduced affinity for PPARγ relative to other TZDs.

UR - http://www.scopus.com/inward/record.url?scp=0032484224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032484224&partnerID=8YFLogxK

U2 - 10.1074/jbc.273.49.32679

DO - 10.1074/jbc.273.49.32679

M3 - Article

VL - 273

SP - 32679

EP - 32684

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 49

ER -